AS research at Baylor University Seeking Viable Treatment Makes Significant Progress The Angelman Syndrome Foundation and the lab of Arthur Beaudet, M.D., at Baylor University are inspired and excited to announce that progress is being made in analyzing a possible […]
Read moreUniversity of North Carolina-Chapel Hill Research Overview and Frequently Asked Questions The Angelman Syndrome Foundation previously supported breakthrough research showing that topoisomerase inhibitors—specifically, topotecan, an FDA-approved drug used in cancer treatments—activates the paternal allele of Ube3a, identifying a possible treatment […]
Read moreAngelman Syndrome Foundation Invests $1.25 Million in Research The Angelman Syndrome Foundation (ASF) announced today that because of the generosity of its supporters the organization has awarded $1.25 million to six research grants focused on finding treatments and defining the […]
Read moreDrug compounds continue to show promise in activating Ube3a in Angelman syndrome mouse model Dr. Benjamin Philpot’s lab at the University of North Carolina Chapel Hill continues to make headway in identifying drug compounds that may lead to a viable treatment […]
Read moreAngelman Syndrome Foundation-Funded Research Identifies Miscommunication of Neurons, New Drug Compound that May Lead to Treatments The Angelman Syndrome Foundation (ASF) announced today that ASF-funded research has uncovered in more depth how Angelman syndrome, a neurodevelopmental disorder similar to autism, […]
Read moreResearch Reveals Possible Root Cause of Seizures in Autism-related Angelman Syndrome Research published on June 6th in the scientific peer-reviewed journal Neuron has discovered the possible underlying cause of seizures in individuals with Angelman syndrome, a neuro-genetic disorder similar to autism that […]
Read moreResearch Reveals Possible Treatment for Autism-related Angelman Syndrome Research published today in the scientific peer-reviewed journal Nature has discovered a potential treatment for Angelman syndrome, a neuro-genetic disorder similar to autism that occurs in one in 15,000 live births. By creating the […]
Read moreNew Angelman Research Collaborative Partnership Announcement The Canadian Angelman Syndrome Society (CASS) and Angelman Syndrome Foundation (ASF) today formally announce a collaborative research partnership to fund the Expert Panel on Challenging and Difficult to Treat Behaviors in Angelman Syndrome (AS). […]
Read more